|  |  |
| --- | --- |
| **Press Release** | **Tuesday 19 June 2018** |

**Sativa Investments PLC**

**(“Sativa” or “the Company”)**

**Sativa appoints pharmacologist Sir Alasdair Breckenridge to its Advisory Board**

Sativa Investments PLC (NEX:SATI), the UK’s only medicinal cannabis investment vehicle, has appointed Sir Alasdair Breckenridge to its Advisory Board, whose medical career as a pharmacologist totals close to 60 years. Sir Breckenridge liaises with the Home Office and the Medicines and Healthcare products Regulatory Agency (“MHRA”), which he has chaired, for the legalisation of medicinal cannabis in the UK.

In the 1995 Birthday Honours for services to medicine and to healthcare, Sir Breckenridge was appointed Commander of the Order of the British Empire and received his knighthood in the 2004 New Year Honours for services to medicine. His clinical pharmacology career includes research on hypertension, being one of the first to link insulin resistance with cardiovascular disease, oral contraceptive steroids, drug metabolism, onchocerciasis, malaria, HIV and various other fields and treatments.

Along with chairing the MHRA, Sir Breckenridge has also chaired the Committee on Safety of Medicines and the Emerging Science and Bioethics Advisory Committee, and was member of the Medical Research Council. He was professor for clinical pharmacology at the University of Liverpool until 2002 and was a senior lecturer at the Hammersmith Hospital and the Royal Postgraduate Medical School from 1964 to 1974. His awards include the Paul Martini prize in Clinical Pharmacology in 1974 and the Goulstonian lecturership at the Royal College of Physicians in 1975.

Geremy Thomas, founder and Chief Executive Officer of Sativa Investments, said: “Sir Breckenridge’s high standing in society and the industry, along with his work with the Home Office and MHRA, puts the Company in good stead to be at the forefront of the UK’s medicinal cannabis industry when the law is updated.

“The Government is now reviewing its stance on medicinal cannabis and Alasdair’s vast experience and knowledge in pharmacology will help Sativa make the right investments in medicinal cannabis.”

Sir Alasdair Breckenridge, Advisory board member of Sativa Investments, said: “I am pleased to be joining the Advisory Board of Sativa, at this time when a Government review of the medical use of cannabinoids is imminent.”

The Directors of the Company accept responsibility for the content of this announcement.

**- Ends -**

For further information please contact:

|  |  |
| --- | --- |
| Geremy Thomas  Founder & Chief Executive Officer  Sativa Investments PLC  +44 (0) 20 7971 1255  [enquiries@sativainvestments.co.uk](mailto:enquiries@sativainvestments.co.uk) | Mark Blower  Executive Director  Sativa Investments PLC  +44 (0) 20 7971 1255  [enquiries@sativainvestments.co.uk](mailto:enquiries@sativainvestments.co.uk) |
| **NEX Exchange Corporate Adviser**  Guy Miller  Peterhouse Capital Limited  +44 (0) 20 7469 0930  [gm@peterhousecap.com](mailto:gm@peterhousecap.com) |  |
| **Financial PR and IR**  Julian Bosdet / Dylan Mark /  Alejandra Campuzano  Abchurch Communications  +44 (0) 20 7469 4630  [SativaInvestments@abchurch-group.com](mailto:SativaInvestments@abchurch-group.com) |  |

**Notes to Editors**

Sativa will look for well-placed opportunities within the dynamic regulatory environment of the Medicinal Cannabis sector and the Company's investment strategy will focus on the production, testing and compliance, research and development, including pharmacology, commercialisation and sales and marketing of Medicinal Cannabis in jurisdictions where it is regulatorily accepted, with an initial focus on Canada. The Company has committed to an independent legal review prior to each investment to verify compliance with the prevailing regulatory environment.

The Company's equity interest in a proposed investment may range from a minority position, to a controlling interest, or to 100 per cent ownership. The ventures that Sativa intends to acquire can either be public or private. Sativa Investments’ first two deals include Canadian-based, tri-listed, emerging global pharmaceutical company, Veritas Pharma Inc., and Toronto-based Pharma-Tech company that owns the patent-pending proprietary QuickStrip™ technology, Rapid Dose Therapeutics Inc.

The Company's Board and Medical Cannabis Advisory Board have a combined 60 years' industry experience with strong and extensive contacts in the industry, with significant pharmaceutical strength and experience. Their extensive skills range from capital fund raisings, medical research, and start-ups, to pharmaceutical development.

For more information on Sativa Investments, please visit: <https://sativainvestments.com/>